Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. (Q36130090)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Lisa M Butler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Jeffry L Dean

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Kathleen McClendon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Wayne D Tilley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Agnieszka K Witkiewicz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Erik S Knudsen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

15 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Cell Cycle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

2756-2761

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

7 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Biological determinants of endocrine resistance in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Tailoring to RB: tumour suppressor status and therapeutic response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Modelling breast cancer: one size does not fit all.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Molecular portraits of human breast tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Towards a molecular basis for tamoxifen resistance in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Targeting the RB-pathway in cancer therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Treatment of growing teratoma syndrome

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3409015

Cancer: Macrophages limit chemotherapy

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22767154

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/CC.21195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22767154%20AND%20SRC:MED&resulttype=core&format=json